Pub Date : 2014-04-01DOI: 10.3969/J.ISSN.1007-3969.2014.03.005
Chen Jiang-fan, Li Chun-ying, Sun Xiu-juan, Zheng Shao-guang
Background and purpose:The non-small cell lung cancer(NSCLC) has been the highest disease incidence in lung cancer,sputum cytology diagnosis has become an important adjunct to the early diagnosis of lung cancer.The purpose of this study was to investigate the value of thinprep cytological and immunocytochemical method in differentiatial diagnosis of exfoliated cells of malignant sputum in NSCLC.Methods:Sputum samples were detected with thinprep cytology test,a total of 530 cases suspicious tumor cells and malignant tumor cells sputum specimens were randomly selected in continuous paraffin-embedded sections,respectively,NSCLC tumor cell markers CK7,CK5/6,TTF-1,P63,EMA were evaluted by immunocytochemical staining.Results:Of the 530 cases of malignant sputum,these were confirmed 265 cases of lung adenocarcinoma,246 cases of squamous carcinoma,19 cases of adeno-squamous carcinoma.Moreover,TTF-1 and CK7 were significantly higher expressed in adenocarcinoma,the positive rates were 92.45%(245/265) and 91.70%(243/265);CK5/6 and P63 were significantly higher expressed in squamous carcinoma,the positive rates were 97.15%(239/246) and 99.59%(245/246).Conclusion:Liquid-based cytology combined with immunocytochemistry had important clinical value in classification and identification of sputum samples,the combination of CK7,CK5/6,TTF-1,P63,EMA can be used for classification and identification of malignant sputum samples between NSCLC,is worthy of promoting in clinical cytopathology diagnosis.
{"title":"The non-small cell lung cancer diagnosis by thinprep cytology test and immunocytochemistry in sputum exfoliated cells","authors":"Chen Jiang-fan, Li Chun-ying, Sun Xiu-juan, Zheng Shao-guang","doi":"10.3969/J.ISSN.1007-3969.2014.03.005","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2014.03.005","url":null,"abstract":"Background and purpose:The non-small cell lung cancer(NSCLC) has been the highest disease incidence in lung cancer,sputum cytology diagnosis has become an important adjunct to the early diagnosis of lung cancer.The purpose of this study was to investigate the value of thinprep cytological and immunocytochemical method in differentiatial diagnosis of exfoliated cells of malignant sputum in NSCLC.Methods:Sputum samples were detected with thinprep cytology test,a total of 530 cases suspicious tumor cells and malignant tumor cells sputum specimens were randomly selected in continuous paraffin-embedded sections,respectively,NSCLC tumor cell markers CK7,CK5/6,TTF-1,P63,EMA were evaluted by immunocytochemical staining.Results:Of the 530 cases of malignant sputum,these were confirmed 265 cases of lung adenocarcinoma,246 cases of squamous carcinoma,19 cases of adeno-squamous carcinoma.Moreover,TTF-1 and CK7 were significantly higher expressed in adenocarcinoma,the positive rates were 92.45%(245/265) and 91.70%(243/265);CK5/6 and P63 were significantly higher expressed in squamous carcinoma,the positive rates were 97.15%(239/246) and 99.59%(245/246).Conclusion:Liquid-based cytology combined with immunocytochemistry had important clinical value in classification and identification of sputum samples,the combination of CK7,CK5/6,TTF-1,P63,EMA can be used for classification and identification of malignant sputum samples between NSCLC,is worthy of promoting in clinical cytopathology diagnosis.","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"24 1","pages":"182-186"},"PeriodicalIF":0.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70177703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-04-01DOI: 10.3969/J.ISSN.1007-3969.2014.03.008
Y. Mei, M. Qi, N. Juan, Qingmei Chen, XU Xiang-yong, Fu Qing-yin, Shang Hong-fang, Zhai Ling-yun, Wang Gang, Zhang Jing
{"title":"Surveillance and early diagnosis of small hepatocellular carcinoma with contrast-enhanced ultrasonography","authors":"Y. Mei, M. Qi, N. Juan, Qingmei Chen, XU Xiang-yong, Fu Qing-yin, Shang Hong-fang, Zhai Ling-yun, Wang Gang, Zhang Jing","doi":"10.3969/J.ISSN.1007-3969.2014.03.008","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2014.03.008","url":null,"abstract":"","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"24 1","pages":"203-207"},"PeriodicalIF":0.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70177718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-03-07DOI: 10.3969/J.ISSN.1007-3969.2014.02.003
Yuan Kui, G. Wen, Zhu Ming-gu
{"title":"Experimental study of mustard seeds prevent colorectal tumor by antioxidation and immune deviation","authors":"Yuan Kui, G. Wen, Zhu Ming-gu","doi":"10.3969/J.ISSN.1007-3969.2014.02.003","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2014.02.003","url":null,"abstract":"","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"24 1","pages":"93-98"},"PeriodicalIF":0.0,"publicationDate":"2014-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70177312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-02-26DOI: 10.3969/J.ISSN.1007-3969.2013.08.001
Zheng Ying, Wu Chunxiao, Zhang Minlu
The incidence, mortality and survivorship of female breast cancer in China, and the distribution of its several key characteristics were described briefly in this article. The breast cancer incidence and mortality rates among Chinese women were increasing rapidly, especially in rural area during the recent 10 years, though they were still in low level worldwidely. The distribution of breast cancer incidence and mortality among Chinese women by age and district were showing significant characters. The total survival rate was estimated to be closed to the average level of developing countries, while disparity between urban and rural area was recognized. Because of lacking population data, it is difficult to describe the characteristics on histological subtypes, stages on diagnosis and molecular subtypes nationwide. The national strategies on breast cancer prevention and control should be focused on disease surveillance,etiological research and survival study. Moreover, measurement should be taken to improve the capacity on breast cancer prevention, screening and clinical services in rural area, in order to narrow the gap of survivorship between urban and rural area and control the rapid increase of mortality in rural area.
{"title":"The epidemic and characteristics of female breast cancer in China","authors":"Zheng Ying, Wu Chunxiao, Zhang Minlu","doi":"10.3969/J.ISSN.1007-3969.2013.08.001","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2013.08.001","url":null,"abstract":"The incidence, mortality and survivorship of female breast cancer in China, and the distribution of its several key characteristics were described briefly in this article. The breast cancer incidence and mortality rates among Chinese women were increasing rapidly, especially in rural area during the recent 10 years, though they were still in low level worldwidely. The distribution of breast cancer incidence and mortality among Chinese women by age and district were showing significant characters. The total survival rate was estimated to be closed to the average level of developing countries, while disparity between urban and rural area was recognized. Because of lacking population data, it is difficult to describe the characteristics on histological subtypes, stages on diagnosis and molecular subtypes nationwide. The national strategies on breast cancer prevention and control should be focused on disease surveillance,etiological research and survival study. Moreover, measurement should be taken to improve the capacity on breast cancer prevention, screening and clinical services in rural area, in order to narrow the gap of survivorship between urban and rural area and control the rapid increase of mortality in rural area.","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"23 1","pages":"561-569"},"PeriodicalIF":0.0,"publicationDate":"2014-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70176467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-02-17DOI: 10.3969/J.ISSN.1007-3969.2013.12.004
Wen Jiang-mei, Lin Shao-jun
{"title":"Adjuvant treatment for squamous cell carcinoma of head and neck after definitive surgery","authors":"Wen Jiang-mei, Lin Shao-jun","doi":"10.3969/J.ISSN.1007-3969.2013.12.004","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2013.12.004","url":null,"abstract":"","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"23 1","pages":"954-960"},"PeriodicalIF":0.0,"publicationDate":"2014-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70176576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-02-14DOI: 10.3969/J.ISSN.1007-3969.2014.01.011
YU Qi-he, Z. Wen
{"title":"Association between microRNA expression and chemotherapy in colorectal cancer","authors":"YU Qi-he, Z. Wen","doi":"10.3969/J.ISSN.1007-3969.2014.01.011","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2014.01.011","url":null,"abstract":"","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"24 1","pages":"62-68"},"PeriodicalIF":0.0,"publicationDate":"2014-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70176905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-01-01DOI: 10.3969/J.ISSN.1007-3969.2013.05.002
Gao Zhiqiang, Han Baohui, Shen Ce, Jin Xian-qiao, Dong Jingcheng, Wan Huan-ying, T. Jie, S. Jie, Gu Ai-qin, Jiang Li-yan
Background and purpose: Excision repair cross-complementing 1(ERCC1) has been associated with cisplatin resistance.The study aimed to explore the role and clinical significance of detection of ERCC1 protein in individualized therapy of advanced non-small cell lung cancer(NSCLC) patients.Methods: From Aug.2006 to Jul.2009,222 stage ⅢB/Ⅳ NSCLC patients were enrolled.The expressions of ERCC1 protein in advanced stage NSCLC tissues were qualitatively detected by immunohistochemical methods.Patients were randomly assigned in a 2∶1 ratio to either the individualized treatment group or the standard treatment group before ERCC1 assessment.Patients in the control arm received gemcitabine plus cisplatin or vinorelbine plus cisplatin.In the genotypic arm,patients with low ERCC1 levels received gemcitabine plus cisplatin or vinorelbine plus cisplatin,and those with high levels received gemcitabine plus vinorelbine.Main outcome measures include response rate,overall survival and time to progression.Differences between the groups were statistically analyzed by chi-square test.Survival differences were analyzed by temporal inspection and Kaplan-Meier survival curves.Results: Follow-up data was up to Sep.30,2012.Objective response was obtained by 20 patients(26.6%) in the standard treatment group and 40 patients(27.2%) in the individualized treatment group(P=0.931).One year survival rate was 40.0% in the standard treatment group and 48.3% in the genotypic arm(P=0.24).The median survival time was 10.2 months(95%CI was 8.67 months to 11.73 months) in the standard treatment group and 13.3 months(95%CI was 12.46 months to 14.14 months) in the individualized treatment group(P=0.041).The time to progression was 4.8 months(95%CI was 4.12 months to 5.48 months) in the standard treatment group and 4.7 months(95%CI was 3.88 months to 5.52 months) in the individualized treatment group(P=0.395).Conclusion: The median survival time has extended in the individualized treatment group.But individualized therapy in advanced NSCLC guiding by detection of ERCC1 protein has not reflected advantage in response rate,overall survival and time to progression.Additional studies are warranted to optimize detections of biomarkers in guiding rational clinical chemotherapy regimens.
{"title":"Clinical research of individualized therapy in advanced non-small cell lung cancer guiding by detection of ERCC1 protein","authors":"Gao Zhiqiang, Han Baohui, Shen Ce, Jin Xian-qiao, Dong Jingcheng, Wan Huan-ying, T. Jie, S. Jie, Gu Ai-qin, Jiang Li-yan","doi":"10.3969/J.ISSN.1007-3969.2013.05.002","DOIUrl":"https://doi.org/10.3969/J.ISSN.1007-3969.2013.05.002","url":null,"abstract":"Background and purpose: Excision repair cross-complementing 1(ERCC1) has been associated with cisplatin resistance.The study aimed to explore the role and clinical significance of detection of ERCC1 protein in individualized therapy of advanced non-small cell lung cancer(NSCLC) patients.Methods: From Aug.2006 to Jul.2009,222 stage ⅢB/Ⅳ NSCLC patients were enrolled.The expressions of ERCC1 protein in advanced stage NSCLC tissues were qualitatively detected by immunohistochemical methods.Patients were randomly assigned in a 2∶1 ratio to either the individualized treatment group or the standard treatment group before ERCC1 assessment.Patients in the control arm received gemcitabine plus cisplatin or vinorelbine plus cisplatin.In the genotypic arm,patients with low ERCC1 levels received gemcitabine plus cisplatin or vinorelbine plus cisplatin,and those with high levels received gemcitabine plus vinorelbine.Main outcome measures include response rate,overall survival and time to progression.Differences between the groups were statistically analyzed by chi-square test.Survival differences were analyzed by temporal inspection and Kaplan-Meier survival curves.Results: Follow-up data was up to Sep.30,2012.Objective response was obtained by 20 patients(26.6%) in the standard treatment group and 40 patients(27.2%) in the individualized treatment group(P=0.931).One year survival rate was 40.0% in the standard treatment group and 48.3% in the genotypic arm(P=0.24).The median survival time was 10.2 months(95%CI was 8.67 months to 11.73 months) in the standard treatment group and 13.3 months(95%CI was 12.46 months to 14.14 months) in the individualized treatment group(P=0.041).The time to progression was 4.8 months(95%CI was 4.12 months to 5.48 months) in the standard treatment group and 4.7 months(95%CI was 3.88 months to 5.52 months) in the individualized treatment group(P=0.395).Conclusion: The median survival time has extended in the individualized treatment group.But individualized therapy in advanced NSCLC guiding by detection of ERCC1 protein has not reflected advantage in response rate,overall survival and time to progression.Additional studies are warranted to optimize detections of biomarkers in guiding rational clinical chemotherapy regimens.","PeriodicalId":10041,"journal":{"name":"China Oncology","volume":"23 1","pages":"328-333"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70176797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：